Albany, NY, Feb. 09, 2018 -- Transparency Market Research prognosticates that the neurorehabilitation devices market would expand at a stellar CAGR of 15.50% over the period from 2016 to 2024. The market value is expected to rise from US$894.9 mn in 2015 to a robust figure of US$3.2 bn by 2024. Based on application, these devices find extensive use for curing and relieving the ailment caused Parkinson’s disease. Geographically, North America and Europe are anticipated to outdo all other regional markets. The prominence of the healthcare infrastructure along with the proficiency of medical personnel are expected to drive these regional market.
Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12791
Heavy Prevalence of Parkinson’s Disease Calls for Greater Demand
The growth of neurological disorders has escalated demand within the market. Parkinson’s disease has especially been a major matter of concern within the medical circles. This has risen the demand for neurorehabilitation devices because several healthcare units and practitioners now find these devices indispensable. Furthermore, the rising toll of patients who are diagnosed with neurological disorders such as traumatic brain injury, strokes, cerebral palsy, and spinal cord injury has been plaguing the healthcare industry. Governments across the globe have assisted in the purchase and installation of neurorehabilitation devices, thus, enhancing the prospects of market growth. Patients who have been suffering for prolonged periods have seen some hope in the form of advancements in technology. The nascent devices for neurorehabilitation are being welcomed by the healthcare industry in order to alleviate the burden of treatments. A peculiar factor driving demand within the market is the rise in the number of road accidents, especially in the Asia Pacific region.
Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12791
High Costs of Implementation Inhibit Market Growth
Despite the rapid growth of the market, a number of factors still inhibit the smooth flow of the market. The lack of skilled surgeons and medical practitioners in developing countries has been a major downfall for the global market. Furthermore, the emerging economies are not in a position to make fundamental changes to their medical framework. Since neurorehabilitation devices incur high costs of implementation, the market is restrained in the financially weak regions. The lack of awareness in a number of regions also places a negative scar on the market. Nevertheless, the need to effectively treat neurological disorders will keep bolstering the stakes of the market.
Buy Neurorehabilitation Devices Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=12791<ype=S
Neurorehabilitation devices have immense utility across the medical fraternity which has led to the rise of a number of players within the market. Hence, the global neurorehabilitation device market manifests a highly competitive vendor landscape. The top three players in the market held more than 50% of the total market share, reflecting the difficulties associated with the entry of new players into the market. These leading players are Medtronic, St. Jude Medical, and Hocoma; all of these players are expected to keep innovating their offerings in order to retain their dominance. The technological advancements coupled with the breakthroughs made in the domain of brain research have given an impetus to the development of neurorehabilitation facilities. The market players are on their toes to utilize the opportunities that lie within the market and gain a higher market share by offering better products. The leading market players have embraced key technologies such as Internet of Things (IoT), nanotechnology, and robotics in order to enhance their product portfolio. The lucrativeness of the market has prompted these players to stay abreast of the latest developments and harness them with immediate effect. St. Jude Medical introduced Proclaim ELITE which is the first of its kind system meant for relieving pain through a spinal cord stimulation system.
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact
Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



